COVID-19 Impact on Patients with Immune-Mediated 5 **Rheumatic Disease: A Comparative Study of Disease Activity** 6 and Psychological Well-Being Over Six Months 7

Claudia Marques^{1*¶}, Marcelo M Pinheiro^{2¶}, Jennifer Lopes^{3&}, Sandra Lúcia Euzébio 8 Ribeiro^{4&}, Mary Vânia Marinho de Castro^{4&}, Lilian David de Azevedo Valadares^{5&}, 9 Aline Ranzolin^{5&}, Nicole Pamplona Bueno de Andrade^{6&}, Rafaela Cavalheiro do 10 Espírito Santo^{6&}., Nafice Costa Araújo^{7&}, Cintya Martins Vieira^{8&}, Valéria Valim^{9&}, 11 Flavia Patricia Sena Teixeira Santos^{10&}, Laurindo Ferreira da Rocha Junior^{11&}, 12

Adriana Maria Kakehasi^{10¶}, Ana Paula Monteiro Gomides Reis^{12¶}, Edgard Torres 13

dos Reis-Neto², Gecilmara Salviato Pileggi², Gilda Aparecida Ferreira¹⁰, Licia 14 Maria Henrique da Mota¹³, Ricardo Machado Xavier⁶. 15

16

2

51 Abstract

52 Objectives: To compare the impact of COVID-19 on clinical status and psychological
53 condition in patients with immune-mediated rheumatic diseases (IMRD) infected by
54 SARS-CoV-2 with IMRD controls not infected, during a 6-month follow-up.

55 Methods: The ReumaCoV Brasil is a longitudinal study designed to follow-up IMRD patients for 6 months after COVID-19 (cases) compared with IMRD patients no COVID-56 19 (controls). Clinical data, disease activity measurements and current treatment 57 58 regarding IMRD, and COVID-19 outcomes were evaluated in all patients. Disease 59 activity was assessed through validated tools at inclusion and at 3 and 6 months post-COVID-19. The FACIT-F (Functional Assessment of Chronic Illness Therapy) and 60 DASS 21 (Depression, Anxiety and Stress Scale - 21 Items) questionnaires were also 61 applied at 6 months after COVID-19 in both groups before large-scale vaccination. The 62 significance level was set as p < 0.05, with a 95% confidence interval. 63

Results: A total of 601 patients were evaluated, being 321 cases (IMRD COVID-19+) 64 and 280 controls (IMRD COVID-19 -), predominantly female with similar median age. 65 66 No significant differences were noted in demographic data between the groups, including comorbidities, disease duration, and IMRD. Disease activity assessment over a 6-month 67 follow-up showed no significant difference between cases and controls. While mean 68 activity scores did not differ significantly, some patients reported worsened disease 69 activity post-COVID-19, particularly in rheumatoid arthritis (RA) (32.2%) and systemic 70 71 lupus erythematosus (SLE) (23.3%). Post-COVID-19 worsening in RA patients correlated with medical global assessment (MGA) and CDAI scores, with a moderate to 72 73 large effect size. Diabetes mellitus showed a positive association (OR=7.15), while TNF 74 inhibitors showed a protective effect (OR=0.51). Comparing SLEDAI pre- and post-

3

COVID-19, a minority showed increased scores, with few requiring treatment changes.
Fatigue, depression, anxiety, and stress were significantly higher in cases compared to
controls. Worsening disease activity post-COVID correlated with worsened FACIT-F
and DASS-21 stress scale in RA patients. No significant associations were found
between COVID-19 outcomes and post-COVID-19 disease activity or psychological
assessments.

Conclusions: Post-COVID-19 IMRD patients show significant psychological wellbeing deterioration despite similar disease activity scores. The variability in reports on IMRD flares and the potential trigger of SARS-CoV-2 for autoimmune manifestations underline the need for detailed clinical assessment and a comprehensive approach to managing them.

86 Introduction

87 The COVID-19 pandemic caused by the SARS-CoV-2 virus represents one of the greatest public health challenges worldwide. The infection has raised concerns 88 about how the disease behaves in patients with immune-mediated rheumatic diseases 89 90 (IMRD), particularly in terms of flares after infection and immunosuppressive treatment as potential risk factors for COVID-19 severity. Since 2020, much 91 information has been published about the understanding of this association and its 92 implications, but few studies have evaluated rheumatic disease flare prospectively post-93 COVID-19 (1) and existing data are still controversial. 94

95 Some individuals with immune-mediated rheumatic diseases (IMRD) may 96 experience exacerbation following SARS-CoV-2 infection. However, uncertainties 97 persist regarding whether these exacerbations are directly linked to disease activity or 98 represent manifestations associated with COVID-19 itself. The phenomenon

4

commonly referred to as "Long COVID" has been associated with a diverse range of 99 clinical manifestations, encompassing joint pain, fatigue, and psychological symptoms 100 101 like depression and anxiety, which can endure for several months post-infection [2]. In 102 patients with IMRD, the presence of these symptoms may be connected to disease 103 flares, introducing ambiguity in determining the appropriate course of treatment. Additionally, some authors have highlighted psychosomatic aspects or a fibromyalgia-104 like presentation, particularly as the prevalence increased following the initial wave of 105 106 the pandemic. This increase appears to be more correlated with heightened fears, 107 uncertainties, and lockdown strategies, as biological abnormalities such as impaired immune response or viral persistence have not been conclusively identified yet (2). 108

This study aimed to assess the disease activity status in patients with immunemediated rheumatic diseases (IMRD) who had experienced COVID-19, comparing them to those who did not contract the virus, over a 6-month follow-up period. Furthermore, the objective was to delineate the prevalence of fatigue and psychological disorders, including depressive symptoms, anxiety, and stress, and to investigate the potential association of these symptoms with IMRD flares.

Materials and Methods

116 Study design – ReumaCoV Brasil Cohort

This paper presents the protocol for the ReumaCoV-Brasil Registry protocol as described elsewhere (3). Briefly, a prospective observational cohort was carried out in 13 university centers distributed along all five Brazilian geographic regions, including patients with IMRD and COVID-19 and a comparison group (patients with only IMRD), with a follow-up time of 6 months. Patients were evaluated in three consecutive visits: visit 1 (inclusion), visit 2 (3 months) and visit 3 (6 months), from May to

5

December 2020. Disease activity status in the medical record of the most recent consultation, carried out at least in the last 6 months before inclusion, was considered as pre-COVID status. The post-COVID status was that which the patient presented at inclusion in the study.

127 Disease activity evaluation

In all visits, data related to disease activity was collected, using specific validated 128 129 instrument, mentioned here are those included in this analysis: Clinical Disease Activity Index (CDAI)(4) for RA patients, Systemic Lupus Erythematosus Disease 130 131 Activity Index 2000 (SLEDAI-2k) (5)in SLE patients, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)(6) for patients with SpA. Besides the activity scores, 132 133 medical global assessment (MGA) and patient global assessment (PGA) were collected 134 regarding disease activity, using a visual analogue scale (VAS) from 0 to 10 points, being 10 the better score, and the patient opinion regarding DRIM worst since the last 135 visit, also using a VAS from 0 to 10. 136

137 Disease flare definition

- Rheumatoid arthritis: worsening of symptoms compared to the pre-COVID-19
 state plus an increase of 4.5 points in the CDAI and/or need to change treatment
 (7).
- Systemic Lupus Erythematosus: worsening of symptoms compared to the pre COVID-19 state plus an increase at least 4 points in the SLEDAI and/or need
 to change treatment (8).
- Spondyloarthritis: worsening of symptoms compared to the pre-COVID-19
 state plus an increase at least 2 points in BASDAI and/or need to change
 treatment(9).

6

147 **Psychological distress evaluation**

At visit 3, two questionnaires were administered: one to assess fatigue, using
The Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-F)(10),
and other to assess mental symptoms, using The Depression, Anxiety and Stress Scale
(DASS-21)(11).

The FACIT-F Scale is a short, 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The score varies from 0 to 52, and the lower the result, the higher the level of fatigue.

DASS-21 is used as a quantitative measure of distress along the 3 axes of depression (D), anxiety (A) and stress (S) reactions and management. Each of the questions is rated from 0 to 3. Therefore, each of the axes presents partial scores of 0 to 18-24 depending on the number of questions assigned.

The study was registered at Brazilian Registry of Clinical Trials RBR-33YTQC and approved by the Brazilian National Research Council (CONEP) under number 3.955.206. All participants were requested to provide explicit opt-in consent prior to participating in the survey.

164

165 **Statical analysis**

166 The Kolmogorov Smirnoff test was performed to verify the normal distribution 167 of continuous variables. As non-normality was verified, the median was used as a 168 measure of central tendency with the respective interquartile range (IQR).

169 To verify the association among categorical or continuous variables, the chi-170 square or Fisher test and Pearson test were used, respectively. The Mann-Whitney test

171	was used to compare means and to estimate the effect size by calculating the r index
172	and the R squared (R^2). The r index was used to evaluate the correlation between two
173	variables: small effect size: 0.10; medium effect size: 0.30 and large effect size: 0.50.
174	To determine the effect size (ES) for comparing means, Cohen's d test was used,
175	interpreted as follows: 0.2 to 0.3 for small effect (the difference between the groups is
176	subtle); around 0.5 as medium effect (moderate difference between the groups) and 0.8
177	or more as large effect (substantial difference between the groups). To compare the
178	variables across three visits, the One-way Anova test (CI 95%) was used for repeated
179	measures.
180	For this analysis, the SPSS statistical package, version 29.0.2.0 and the Graph
181	Pad Prism software, Version 10.1.1 (270), November 21, 2023, were used. The

significance level was set at p < 0.05, with 95% confidence interval.

183

182

184 **Results**

A total of 601 patients were evaluated, including 321 cases (IMRD COVID+) and 280 controls (IMRD COVID-), with the majority being female with similar median age. No differences were observed regarding demographic data between the two groups, including comorbidities, disease duration and IMRD. A higher frequency of social isolation was observed in the control group (p=0.001), as well as they were on TNFi treatment (p=0.003). Table 1 summarizes the clinical and demographic data at baseline.

192

193

195 Table 1. Clinical and demographic data of the sample, comparing IMRD patients with COVID-

19 versus without COVID-19 at baseline. Chi square test, unless otherwise noted. 196

n % n % p-value Female 275 85.7 237 84.6 0.724 Age (median, IQR) 46 (37-57) 49 (38-57) 0.135** 0.135** Ethniciy White 105 32.7 99 35.3 0.601 Instruction 0.3 2 0.7 0.631 0.631 Instruction 1 0.3 2 0.7 0.631 Security 8 2.4 75.4 204 72.8 Profession		Cases (IMRD COVID +) n=321		Controls (IMRD COVID N=280	-)	
Female 275 85.7 237 84.6 0.724 Reg (median, IQR) 46 (37-57) 90 (38-57) 0.136** Ethnicity 105 2.7 90 35.3 0.601 Nor-white 216 67.3 181 64.7 0.601 Instruction 1111 0.3 2 0.7 0.631 78 24.3 74 26.5 26 Profession 2 10.0 13 4.7 0.631 Education 32 10.0 25 9.0 9.0 Housevife 90 28.1 77 27.6 0.083 Coberty 16 36.0 129 45.9 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities 7 22 7.9 0.438 15.0 34 12.1 0.317 Diabase 31 9.7 22 7.9 0.438 0.602			%		%	P-value
Age (median, IQR) 46 (37-57) 49 (38-57) 0.136** Ethnicity 105 32.7 99 35.3 0.601 Instruction 105 32.7 99 35.3 0.601 Instruction 11 64.7 0.631 0.631 Instruction 11 0.3 2 0.7 0.631 Segard S	Female					
Ethnicity White 105 32.7 99 35.3 0.601 Non-white 216 67.3 1181 64.7 1 Instruction 1 0.3 2 0.7 0.631 \leq 8 years 78 24.3 74 26.5 2 \geq 8 years 78 24.3 74 26.5 2 Profession - - - - 0.030 Health 34 10.6 13 4.7 - Security 8 2.5 3 1.1 - Housevife 90 2.5 188 67.1 0.001 Comorbidities - - - - - Others 116 36.0 129 45.9 - 0.258 Social isolation 162 50.5 188 67.1 0.001 Comorbidities - - - - - Diabacis 31<			0017		0.110	
White 105 32.7 99 35.3 0.601 Instruction 216 67.3 181 64.7 1 Instruction 1 0.3 2 0.7 0.631 < 8 years 78 24.3 74 26.5 1 Profession 1 1 2.8 3.3 1.1 0.030 Profession 1 1.8 3.3 1.1 0.030 1 1 0.030 Material 34 10.6 13 4.7 1 0.050 1 1 0.030 1 1 0.080 1 1.1 0.001 1 1 1 0.051 1 1 0.051 1 1 1 0.051 1 1 0.051 1 1 1 0.051 1 1 0.051 1 1 1 0.051 1 1 0.051 1 0.051 1 0.051 1 0.051 1		10 (07 07)				01120
Non-white 216 67.3 181 64.7 Instruction 1 0.3 2 0.7 0.631 $< \delta$ years 78 24.3 74 26.5 0.7 $> \delta$ years 78.2 75.4 204 72.8 74 Profession 78 2.5 3 1.1 0.30 Readin 32 10.0 25 9.0 0.030 Heatin 34 10.0 25 9.0 0.044 Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities		105	32.7	99	35.3	0.601
Instruction Image: structure in the image in the image. The image is the image in						0.001
Illucrate 1 0.3 2 0.7 0.631 < 8 years 78 24.3 74 26.5 0 > 8 years 78.4 204 72.8 0 0 Profession 1 12.8 33 11.7 0.030 Health 34 10.6 13 4.7 0 Security 8 2.5 3 1.1 0 0.030 Housewife 90 28.1 77 27.6 0 0 Active at work 166 51.9 122 44.8 0.001 Social isolation 162 50.5 188 67.1 0.001 Comorbidities 1123 38.3 120 42.9 0.258 Obesin 48 15.0 34 12.1 0.317 Diabetes 31 9.7 22 7.9 0.438 Ling disease 20 6.2 16 5.7 0.790 Ca		210	0710	101	0.117	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		1	0.3	2	0.7	0.631
$> \delta$ years 242 75.4 204 72.8 Profession $Public$ attendance 41 12.8 33 11.7 Realth 34 10.6 13 4.7 Security 8 2.5 3 1.1 Education 32 10.0 25 9.0 Housewife 90 28.1 77 27.6 Others 116 36.0 129 45.9 Active at work 106 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities		-		-		0.001
Profession m m m m m Public attendance 41 12.8 33 11.7 0.030 Realth 34 10.6 13 4.7 Security 8 2.5 3 1.1 Education 32 10.0 25 9.0 Medication 166 51.9 129 45.9 Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities 12.1 0.317 Diabetes 31 9.7 22 7.9 0.438 Lung disease 20 6.2 16 5.7 0.790 Kidney disease 20 6.2 16 5.7 0.790 Stationally 12 4.3 13 4.6 0.602 Smoking 11 3.7 15 4.6 0.580 <						
Public attendance 41 12.8 33 11.7 0.030 Health 34 10.6 13 4.7 Security 8 2.5 3 1.1 Education 32 10.0 25 9.0 Housevefe 90 28.1 77 27.6 Others 116 36.0 129 45.9 Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities - - - - - Mypertension 123 38.3 120 42.9 0.258 Obesity 48 15.0 34 12.1 0.317 Diabetes 20 6.2 16 5.7 0.790 Kidney disease 20 6.2 16 5.7 0.734 Subsing 11 3.7 15 4.6 0.835		2.12	,	201	,210	
Health 34 10.6 13 4.7 Security 8 2.5 3 1.1 Education 32 10.0 25 9.0 Mousewife 90 28.1 77 27.6 Others 116 36.0 129 45.9 Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities 123 38.3 120 42.9 0.258 Obesity 48 15.0 34 12.1 0.317 Diabetes 31 9.7 22 7.9 0.438 Lung disease 20 6.2 16 5.7 0.790 Cardiopathy 12 4.3 13 4.6 0.580 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.85 <		41	12.8	33	11.7	0.030
Security 8 2.5 3 1.1 $Education$ 32 10.0 25 9.0 $Houssevife$ 90 28.1 77 27.6 $Others$ 116 36.0 129 45.9 Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities						0.000
Education 32 10.0 25 9.0 Housewife 90 28.1 77 27.6 Others 116 36.0 129 45.9 Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities - - - - - Obesity 48 15.0 34 12.1 0.317 Diabetes 31 9.7 22 7.9 0.438 Lang disease 20 6.2 16 5.7 0.790 Kidney disease 20 6.2 16 5.7 0.790 Stand disputs 107 33.3 99 35.4 0.602 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.337 Bignosis I1 3.4 112 39.4		-				
Housewife 90 28.1 77 27.6 $Others$ 116 36.0 129 45.9 Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities						1
Others 116 56.0 129 45.9 Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities - - - - - Mignet perfension 123 38.3 120 42.9 0.258 Obesity 48 15.0 34 12.1 0.317 Diabetes 31 9.7 22 7.9 0.438 Cardiopathy 12 4.3 13 4.6 0.7390 Kidney disease 20 6.2 16 5.7 0.790 Cardiopathy 12 4.3 13 4.6 0.580 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.835 Diagnosi - - - -						1
Active at work 166 51.9 125 44.8 0.084 Social isolation 162 50.5 188 67.1 0.001 Comorbidities 123 38.3 120 42.9 0.258 Hypertension 123 38.3 120 42.9 0.258 Obesity 48 15.0 34 12.1 0.317 Diabetes 31 9.7 22 7.9 0.438 Lung disease 20 6.2 16 5.7 0.790 Kidney disease 20 6.2 16 5.7 0.790 Cardiopathy 12 4.3 13 4.6 0.734 Smoking 11 3.7 15 4.6 0.602 Ethilism 10 3.1 8 2.8 0.835 Diagnosis $I1$ 3.4 4.12 36.4 Systemic sclerosis 17 5.3						1
Social isolation 162 50.5 188 67.1 0.001 Comorbidities		-				0.084
Comorbidities Image: space of the system is a space of				-	-	
Hypertension 123 38.3 120 42.9 0.258 Obesity 48 15.0 34 12.1 0.317 Diabetes 31 9.7 22 7.9 0.438 Lung disease 20 6.2 16 5.7 0.790 Kidney disease 20 6.2 16 5.7 0.790 Cardiopathy 12 4.3 13 4.6 0.734 No comorbidities 107 33.3 99 35.4 0.602 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.835 Diagnosi - - - - - RA 93 28.9 105 37.0 - Axial SpA 2.3 7.1 30 10.6 - Systemic sclerosis 17 5.3 1.8 - - Mopathy 7 2.2		102	50.5	100	0/.1	0.001
Obesity 48 15.0 34 12.1 0.317 Diabetes 31 9.7 22 7.9 0.438 Lung disease 20 6.2 16 5.7 0.790 Kidney disease 20 6.2 16 5.7 0.790 Cardiopathy 12 4.3 13 4.6 0.734 No comorbidities 107 33.3 99 35.4 0.662 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.835 Diagnosis 10 3.1 8 2.8 0.835 Sigmin carlinitiis 21 6.5 12 36.4 Systemic sclerosis 17 5.3 10 3.6 Systemic sclerosis 17 5.3 1.8 1.4 Miopathy 7 2.2 2 0.7 1.4 Others 11 3.4 4 1.4 <td></td> <td>123</td> <td>38.3</td> <td>120</td> <td>42.9</td> <td>0.258</td>		123	38.3	120	42.9	0.258
Diabetes 31 9.7 22 7.9 0.438 Lung disease 20 6.2 16 5.7 0.790 Kidney disease 20 6.2 16 5.7 0.790 Cardiopathy 12 4.3 13 4.6 0.734 No comorbidities 107 33.3 99 35.4 0.602 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.835 Diagnosis Image: SLE 137 42.5 112 39.4 $R/4$ 93 28.9 105 37.0 105 $R/4$ 93 28.9 105 37.0 10 $Systemic sclerosis$ 17 5.3 10 3.6 11 $Systemic sclerosis$ 17 2.2 0.7 10 10 Mopathy 7 2.2 0.7 10 10 10 Miopathy <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Lung disease 20 6.2 16 5.7 0.790 $Kidney$ disease 20 6.2 16 5.7 0.790 $Cardiopathy$ 12 4.3 13 4.6 0.734 No comorbidities 107 33.3 99 35.4 0.602 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.835 Diagnosis Image: SLE 137 42.5 112 39.4 0.183 $Axial SpA$ 23 7.1 30 10.6 0.183 $Psoriatic arthritis$ 21 6.5 12 36.4 0.183 $Mipathy$ 7 2.2 2 0.7 0.166** $Mopathy$ 7 2.2 2 0.7 0.146** $Mopathy$ 7 2.2 2 0.7 0.146** $Mostication IMRD$ In 3.4 4 1.4 0.465						
Kidney disease 20 6.2 16 5.7 0.790 $Cardiopathy$ 12 4.3 13 4.6 0.734 No comorbidities 107 33.3 99 35.4 0.602 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.835 Diagnosis - - - - - KA 93 28.9 105 37.0 - - $Axial SpA$ 23 7.1 30 10.6 - - $Systemic sclerosis$ 17 5.3 10 3.6 - - $Miopathy$ 7 2.2 2 0.7 - - - $Miopathy$ 7 2.2 2 0.7 - - - $Miopathy$ 7 2.2 2 0.7 - - - - - - -						
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$						
No comorbidities 107 33.3 99 35.4 0.602 Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.835 Diagnosis SLE 137 42.5 112 39.4 0.183 RA 93 28.9 105 37.0 $Axial SpA$ 23 7.1 30 10.6 $Psoriatic arthritis$ 21 6.5 12 36.4 $Systemic sclerosis$ 17 5.3 10 3.6 $Miopathy$ 7 2.2 2 0.7 $Miopathy$ 7 2.2 2 0.7 $Methotres 11$ 3.4 4 1.4 $Miopathy$ 7 2.2 2 0.7 $Methotres 11$ 3.4 4 1.4						
Smoking 11 3.7 15 4.6 0.580 Ethilism 10 3.1 8 2.8 0.835 Diagnosis III 3.7 42.5 $II12$ 39.4 0.183 RA 93 28.9 105 37.0 0.183 RA 93 28.9 105 37.0 0.183 $Psoriatic arthritis$ 21 6.5 12 36.4 $Systemic sclerosis$ 17 5.3 10 3.6 $Sjögren disease$ 12 3.7 5 1.8 $Miopathy$ 7 2.2 2 0.7 $Others$ 11 3.4 4 1.4 $0.146**$ IQR $0(5-15)$ 10 $10(6-18)$ $0.146**$ $Hydroxychloroquine 137 42.7 109 38.9 0.351 Medication IMRD I I I I I I$						
Ethilism 10 3.1 8 2.8 0.835 Diagnosis $ -$ SLE 137 42.5 112 39.4 0.183 RA 93 28.9 105 37.0 $Axial SpA$ 23 7.1 30 10.6 $Systemic sclerosis$ 17 5.3 10 3.6 $Systemic sclerosis$ 17 5.3 10 3.6 $Sjögren disease$ 12 3.7 5 1.8 $Miopathy$ 7 2.2 2 0.7 Others 11 3.4 4 1.4 0.146^{**} IQR 10 $6-18$ 0.7 0.28 Medication IMRD $ Hydroxychloroquine$ 137 42.7 109 38.9 0.351 Methorexate 72 22.4 73 26.1 0.298						
Diagnosis SLE 137 42.5 112 39.4 0.183 RA 93 28.9 105 37.0 0.183 Axial SpA 23 7.1 30 10.6 Psoriatic arthritis 21 6.5 12 36.4 Systemic sclerosis 17 5.3 10 3.6 Sjögren disease 12 3.7 5 1.8 Miopathy 7 2.2 2 0.7 Others 11 3.4 4 1.4 JRR 10 (5-15) 10 (6-18) 0.146** IQR 10 5-15 0.351 Medication IMRD 139 43.3 113 40.4 0.465 Oral corticosteroid 137 42.7 109 38.9 0.351 Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
SLE 137 42.5 112 39.4 0.183 RA 93 28.9 105 37.0 Axial SpA 23 7.1 30 10.6 Psoriatic arthritis 21 6.5 12 36.4 Systemic sclerosis 17 5.3 10 3.6 Systemic sclerosis 17 2.2 2 0.7 Miopathy 7 2.2 2 0.7 Others 11 3.4 4 1.4 Disease duration, years (median, IQR) 10 (5-15) 10 (6-18) 0.146** Medication IMRD Image: Controcontrol of the thydroxychloroquine 139 43.3 113 40.4 0.465 Oral corticosteroid 137 42.7 109 38.9 0.351 Methotrexate 72 22.4 73 26.1 0.298 Methotrexate 72 22.4 73 26.1 0.298 Methotrexate 72 22.4 73 26.1		10	5.1	0	2.0	0.055
RA 93 28.9 105 37.0 Axial SpA 23 7.1 30 10.6 Psoriatic arthritis 21 6.5 12 36.4 Systemic sclerosis 17 5.3 10 3.6 Sjögren disease 12 3.7 5 1.8 Miopathy 7 2.2 2 0.7 Others 11 3.4 4 1.4 Disease duration, years (median, IQR) 10 (5-15) 10 (6-18) 0.146** Medication IMRD 10 5 1.1 0.22 Medication IMRD 137 42.7 109 38.9 0.351 Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28	0	137	42.5	112	30.4	0.183
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						0.105
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
Systemic sclerosis 17 5.3 10 3.6 Sjögren disease 12 3.7 5 1.8 Miopathy 7 2.2 2 0.7 Others 11 3.4 4 1.4 Disease duration, years (median, IQR) 10 (5-15) 10 (6-18) 0.146** Medication IMRD 139 43.3 113 40.4 0.465 Methotrexate 72 22.4 73 26.1 0.298 Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1	1					
Sjögren disease 12 3.7 5 1.8 Miopathy 7 2.2 2 0.7 Others 11 3.4 4 1.4 Disease duration, years (median, IQR) 10 (5-15) 10 (6-18) 0.146** Medication IMRD 10 (5-15) 10 (6-18) 0.146** Medication IMRD 137 42.7 109 38.9 0.351 Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituxinab 5 1.6 6 2.1 0.762* JAKi 8 2.5 2 0.7 0.115*						
Miopathy 7 2.2 2 0.7 Others 11 3.4 4 1.4 Disease duration, years (median, IQR) 10 (5-15) 10 (6-18) 0.146** Medication IMRD 139 43.3 113 40.4 0.465 Oral corticosteroid 137 42.7 109 38.9 0.351 Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Mycophenolate mofetil 2.5 2 0.7 0.690* Belinnumab 3 0.9 3 1.1						
Others 11 3.4 4 1.4 Disease duration, years (median, IQR) 10 (5-15) 10 (6-18) 0.146** Medication IMRD Image: Constraint of the state of th						1
Disease duration, years (median, IQR) 10 (5-15) 10 (6-18) 0.146** Medication IMRD Image: constraint of the system						1
Hydroxychloroquine 139 43.3 113 40.4 0.465 Oral corticosteroid 137 42.7 109 38.9 0.351 Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591*	Disease duration, years (median,		5.1			0.146**
Oral corticosteroid 137 42.7 109 38.9 0.351 Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591*	Medication IMRD					
Oral corticosteroid 137 42.7 109 38.9 0.351 Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591*	Hydroxychloroquine	139	43.3	113	40.4	0.465
Methotrexate 72 22.4 73 26.1 0.298 TNFi 61 19.0 82 29.3 0.003 Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591*			42.7	109	38.9	0.351
Azathioprine 48 15.0 30 10.7 0.123 Leflunomide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591*	Methotrexate	72	22.4	73		
Leflunmide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*	TNFi	61	19.0	82	29.3	0.003
Leflunmide 36 11.2 23 8.2 0.217 Mycophenolate mofetil 28 8.7 24 8.6 0.948 Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*	Azathioprine	48	15.0	30		0.123
Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*			11.2			0.217
Tocilizumab 14 4.4 23 8.2 0.050 Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*			8.7	24	8.6	0.948
Rituximab 5 1.6 6 2.1 0.762* IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*	Tocilizumab	14		23		
IL-17i 8 2.5 2 0.7 0.115* JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*						
JAKi 8 2.5 4 1.4 0.396* Abatacept 4 1.2 2 0.7 0.690* Belinumab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*					0.7	0.115*
Abatacept 4 1.2 2 0.7 0.690* Belimumab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*	JAKi	8				
Belimunab 3 0.9 3 1.1 0.591* Cyclophosphamide (pulse therapy) 3 0.9 3 1.1 1.000*				2	0.7	
<i>Cyclophosphamide (pulse therapy)</i> 3 0.9 3 1.1 1.000*	1					
0.10 12.1 10.10	Sulfasalazine		0.9	6	2.1	0.316*

197

Chi square test, unless otherwise noted. *Fisher exact test; **Mann-Whitney test; CI 95%. SLE: systemic lupus erythematosus; RA:


198 rheumatoid arthritis; Axial SpA: axial spondyloarthritis; Pso arthritis: psoriatic arthritis; TNFi: tumour necrosis factor inhibitor; IL-17i:

199 interleucine 17 inhibitor; JAKi: janus kinase inhibitor

9

201	In the group of patients with COVID-19 (n=321), the most frequent symptoms
202	were headache (60.6%), fever (55.6%), dysgeusia (54.3%), asthenia (53.7%), anosmia
203	(52.5%) and cough (49.1%). Dyspnea was reported in 35.1% of cases. The medications
204	used to treat COVID-19 were analgesics (53.7%), azithromycin (40.7%), oral
205	corticosteroids (20.2%) and hydroxychloroquine (10.2%), but 16.1% did not use any
206	medication.
207	Regarding COVID-19 outcomes, hospital care was sought by 77 (23.9%)
208	patients and 29 (9.0%) were hospitalized. Of these, 3 patients were admitted to the
209	intensive care unit and used mechanical ventilation. None of the patients died.
210	
211	Disease activity assessment
212	There was no significant difference comparing cases and controls in a 6-month
213	follow-up (V1, V2, and V3), regardless of IMRD (Figure 1).
214	
215	Figure 1. Comparison of disease activity scores across the three study visits (v1, V2 e
216	V3) in patients with systemic lupus erythematosus, measured by SLEDAI (A),
217	rheumatoid arthritis, measured by CDAI (B) and axial spondylarthritis patients,
218	measured by BASDAI, comparing cases and controls matched to sex, age and

219 epidemiological exposition.




CDAI: Clinical Disease Activity Score; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index

- One-way Anova test (CI 95%), repeated measures, multiple comparison of the mean of each column with the mean
- of every other column.

11


Although no difference was demonstrated in the mean activity scores, some patients self-reported worsening of the disease activity after COVID-19 [30 with RA (32.2%), 32 with SLE (23.3%) and 2 with SpA (8.6%)]. Exploring these groups further, we also did not observe any significant difference in the mean activity score in RA and SLE patients (Figure 2).

Figure 2. Comparison of disease activity scores across the three study visits, only in
patients with systemic lupus erythematosus (SLEDAI) (A) and rheumatoid arthritis
(CDAI) (B) who self-reported clinical worsening after COVID-19



237 Visit 1 (inclusion); V2: Visit 2; V3: Visit 3.

238 CDAI: Clinical Disease Activity Score; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.



241

In RA patients that self-reported worsening of disease activity after COVID-19, we applied the flare definition, comparing the CDAI pre-COVID with the CDAI post-COVID (inclusion), visit 2 and visit 3, in a paired way. At inclusion, 12 patients (40.0%) had an increased CDAI \geq 4.5 points compared to pre-COVID status, but only 1 required a change in treatment. At visit 2, compared with visit 1, 5 new patients presented an increased CDAI \geq 4.5 points and 7 patients improved compared to the

248	previous visit.	At visit 3, 12	patients	presented an	n increased	CDAI,	and of these,	8 new
-----	-----------------	----------------	----------	--------------	-------------	-------	---------------	-------

249 patients, who had not worsened at visit 2, and only one needed change of treatment.

- 250 Besides, we compared the tender joint count (TJC), swollen joint count (SJC),
- 251 patient global assessment (PGA) and medical global assessment (MGA) across the
- three visits, no significant difference was observed. Eight patients in this group (26.6%)
- self-reported worsening of joint manifestations.
- 254 Comparing the disease activity in the group of RA patients who self-reported
- 255 worsening with those who did not worse, there was an association with post-COVID
- 256 MGA, assessed at baseline (ES= 0.56; CI95% -1.01 to -0.11, p=0.007) and with CDAI
- and all its components at visit 3 (Table 2).

Table 2. Comparison between Pre- and Post-COVID mean scores in patients with RA who reportedworsening versus those who did not report it in the visit 3

		Worse in	n visit 3			
	N	0	Ye	Yes		
						Independent sample
	Mean	SD	Mean	SD	p-value	effect size (ES)*
CDAI pre-COVID [#]	17.5	16.2	19.2	14.1	0.330	-0.110 (-0.59 to 0.37)
TJC pre-COVID	5.9	6.8	6.4	5.5	0.369	-0.079 (-0.53 to 0.38)
SJC pre-COVID	3.6	6.0	3.3	5.6	0.404	0.057 (-0.40 to 0.51)
PGA pre-COVID	4.8	3.0	8.6	16.4	0.055	-0.385 (-0.85 to 0.087)
MGA pre-COVID	3.2	2.7	3.8	2.6	0.210	-0.196 (-0.66 to 0.27)
CDAI post-COVID ^{&}	19.0	18.4	26.5	19.3	0.040	-0.397 (-0.83 to 0.04)
TJC post-COVID	6.5	8.4	9.7	8.6	0.044	-0.384 (-0.82 to 0.05)
SJC post-COVID	3.1	4.8	4.8	7.0	0.113	-0.271 (-0.70 to 0.16)
PGA post-COVID	5.5	3.1	6.4	2.9	0.090	-0.304 (-0.74 to 0.140)
MGA post-COVID	3.4	2.9	5.0	2.7	0.007	-0.563 (-1.01 to -0.11)
CDAI V3	11.7	9.6	23.6	15.9	0.001	-0.996 (-1.45 to -0.51)
TJC V3	3.5	3.6	7.5	6.9	<0.001	-0.801 (-1.25 to -0.34)
SJC V3	1.3	2.2	4.7	6.3	0.001	-0.818 (-1.27 to -0.36)
MGA V3	2.7	2.3	5.0	2.2	0.001	-1.003 (-1.46 to -0.53)
PGA V3	4.2	2.7	6.8	2.3	0.001	-1.005 (-1.45 to -0.53)

260 CDAI: clinical disease activity score; TJC: tender joint count; SJC: swollen joint count; PGA: patient global
261 evaluation; MGA: medical global evaluation. *Cohen's d test (CI95%): 0.2 to 0.3: Small effect - the difference
262 between the groups is subtle. About 0.5: Medium effect - moderate difference between the groups. 0.8 or more:
263 Large effect - substantial difference between the groups.

264

265

The size effect for MGA post COVID (V1) mean difference means was moderate (-0.56; CI95% -1.01 to -0.11) and for CDAI (-0.996; CI95% -1.45 to -0.51),

13

268	TJC (-0.801; CI 95% -1.25 to -0.34), SJC (-0.818; CI-1.27 to -0.36), MGA (-1.003; CI
269	-1.46 to -0.53) and PGA at V3 (-1.005; CI -1.45 to -0.53) was a large effect,
270	demonstrating substantial difference between the groups.

Post-COVID worsening in patients with RA was associated with diabetes mellitus (OR=7.15; CI95% 1.7-29.4, p=0.005) and protectively with current use of TNF inhibitors before the SARS-CoV-2 infection (OR=0.51; CI95% 0.2-0.9, p=0.026).

274 Among the patients with SLE who self-reported worsening of disease after COVID-19, 10 of them reported the appearance of new clinical manifestations. 275 However, no significant differences were observed regarding gender, age, 276 277 comorbidities, or concomitant medications. Worsening was only associated with anosmia, as a symptom of COVID-19 (OR=2.43; CI95% 1.07-5.52, p=0.03). The self-278 reported clinical manifestations by SLE patients who were worse after COVID-19 279 (n=32) at visit 3 were skin rash (5 patients), arthritis (3 patients), proteinuria (2 patients) 280 and interstitial lung disease (1 patient). 281

Comparing the SLEDAI pre- and post-COVID through the flare definition, we observed that 6 patients (18.0%) had an increased SLEDAI \ge 4.0 points, but only 2 required a change in treatment. At visit 2, compared with visit 1, most patients showed SLEDAI improvement and only 3 patients had it increased at visit 3. However, 3 new patients had an SLEDAI increasing compared with the visit 2.

- Among SpA patients, only 2 patients self-reported worsening after COVID-19 and one of them had progressive worsening in all three visits, based on the BASDAI.
- There was no statistically significant association between COVID-19 outcomes (hospital care, hospitalization, and ICU admission) with post-COVID disease activity at visit 3.

14

292


293 Fatigue, depression, anxiety, and stress assessment


After a 6-month follow-up, a statistically significant difference was observed 294 295 through FACIT and DASS 21 questionnaires in their three domains comparing cases

and controls (Figure 3). 296

297

Figure 3. Comparison among FACIT (A), DASS-21 D (B), DASS-21 A (C) and 298






301 302 303 IQR: Interquartil range. FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue; DASS-21 D: Depression Anxiety and Stress Scale dominium depression; DASS-21 A: Depression Anxiety and Stress Scale dominium anxiety; DASS-21 S: Depression Anxiety and Stress Scale dominium stress.. Mann-Whitney test; CI=95%

304

15

Figure 4. Distribution and comparison among FACIT (A), DASS21 D (B), DASS 21 313 A (C) and DASS 21 S (D) median scores after a 6-month follow-up in patients with 314 315 rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and axial

spondyloarthritis (axSpA) only in cases group (IMRD COVID-19+) 316



318 319 320 321 FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue; DASS-21 D: Depression Anxiety and Stress Scale dominium depression; DASS-21 A: Depression Anxiety and Stress Scale dominium anxiety; DASS-21 S: Depression Anxiety and Stress Scale dominium stress; PsoA: psoriatic arthritis; RA: rheumatoid arthritis; axSpA: axial spondyloarthritis; SLE: systemic lupus erythematosus. Independent-Samples Kruskal-Wallis Test, CI 95%.

322

323

324 There was no association of FACIT or DASS-21 with comorbidities, IMRD endpoints (type and specific therapy), and outcomes related to COVID, such as 325 326 symptoms and treatment, in univariate linear models. Considering the FACIT-F and


16

327 DASS-21 scores, there was not significant correlation between the disease activity in

328 RA and SLE patients from case group (Figure 5).

329

Figure 5. Correlation between disease activity in patients with systemic lupus erythematosus, measured by SLEDAI, and rheumatoid arthritis, measured by CDAI, only in case group (IMRD COVID-19 +), with FACIT-F (A and E) and DASS 21-D (B and F), DASS 21-A (C and G) and DASS 21-S (D and H) scores



334

336	Specifically analyzing the group of patients with worsening of disease activity
337	after COVID-19, we observed that RA patients also had a worsening of FACIT-F (31.5
338	vs. 36.4; p=0.047) and DASS-21-S (19.0 vs. 13.0; p=0.031) when compared to those
339	with no worsening activity. Also, the means was considered as moderate for FACIT <u>-F</u>
340	(0.47; from 0.03 to 0.91) and DASS 21-S (-0.44; from -0.88 to -0.007) (Table 3). In
341	SLE patients, no significant difference was observed.

Table 3. Comparison among mean scores for FACIT, DASS 21-D, DASS 21-A and DASS-21 S in patients with RA who reported worsening versus those who did not report it

•	Worse a					
	No		Yes			
						Independent sample
	Mean	SD	Mean	SD	p-value	effect size*

medRxiv preprint doi: https://doi.org/10.1101/2024.03.18.24304464; this version posted March 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

1	7
т	/

FACIT	36.4	9.7	31.5	11.3	0.017	0.47 (0.03 to 0.91)
DASS 21-D	9.5	10.5	12.6	10.9	0.094	-0.29 (-0.73 to 0.144)
DASS 21-A	11.3	10.0	14.4	9.9	0.090	-0.30 (-0.73 to 0.13)
DASS 21-S	13.7	12.4	19.0	9.7	0.023	-0.44 (-0.88 to -0.007)

344 345

* Cohen's d (CI95%): 0.2 to 0.3: Small effect - the difference between the groups is subtle. About 0.5: Medium effect moderate difference between the groups. 0.8 or more: Large effect - substantial difference between the groups. 346

There was no statistically significant association between COVID-19 outcomes 347 (hospital care, hospitalization, and ICU admission) with FACIT-F and DASS-21 scores 348 at visit 3. 349

350

Discussion 351

Our results demonstrated that the disease activity scores did not differ 352 significantly in IMRD patients during a 6-month follow-up after COVID-19 in 353 354 comparison to those who did not contract the virus. However, the clinical worsening was related to fatigue, depression, anxiety, and stress. 355

Nowadays, the data regarding the association between SARS-CoV-2 infection 356 and IMRD flare are controversial, especially because the published studies have 357 heterogeneous samples and different designs. Consequently, the current uncertainty 358 359 revolves around whether the Patient-Reported Outcomes (PROs) are related to IMRD 360 flare itself after COVID-19 or if it is associated with Long Covid or, alternatively, represent a reactive post-infectious immunological response working a potential trigger 361 (1, 12-15).362

In rheumatic diseases, a flare is defined as any exacerbation of disease activity that, if 363 364 persistent, would typically necessitate the initiation or modification of therapy. It signifies a 365 cluster of symptoms of sufficient duration and intensity to warrant the commencement, 366 alteration, or escalation of therapeutic measures (16). In our study, although there was no

18

discernible difference in mean activity scores among patients with rheumatoid arthritis 367 (RA), systemic lupus erythematosus (SLE), and spondyloarthritis (SpA), a subgroup of 368 patients reported a deterioration in immune-mediated rheumatic disease (IMRD). In 369 370 some of these cases, activity scores increased, aligning with the flare definition 371 employed in this investigation. Given the recognized potential for overestimation of 372 IMRD activity tools in patients with conditions like fibromyalgia (17) and other chronic painful disorders, particularly in RA and axial SpA, it becomes imperative to ascertain 373 374 the presence of "true" disease activity. This determination holds substantial relevance in decision-making processes related to treatment adjustments. Nevertheless, we 375 observed an association between patients' self-reported worsening after 6 months and 376 377 the Clinical Disease Activity Index (CDAI) score, along with all its individual components, including swollen joint count (SJC). This association suggests a plausible 378 occurrence of flare in this specific subset of patients. 379

A cross-sectional study, including 32 patients with RA and SpA, demonstrated 380 381 no relevant change regarding disease activity after COVID-19 in those who interrupted 382 their treatment (1). Data from the COVAD study, a cohort that evaluated 824 patients with IMRD who had at least one SARS-CoV-2 infection, between March 2021 and 383 June 18, 2022 (12), showed that 36.9% of patients experienced at least one flare of the 384 underlying IMRD following COVID-19 infection over a 127 day period (IQR = 62-385 308 days) from the date of infection to the date of the survey. Females and patients with 386 comorbidities had higher odds of flaring of their disease. Patients who reported flares 387 388 had worse physical health scores, pain VAS, fatigue VAS, and lower mental health scores compared to those who did not report flares. However, as stated by the authors, 389 390 "this was a self-reported disease flares without verification by a physician which could

19

be impacted by patients' perceptions of flares and their inability to distinguish fromongoing symptoms of long-COVID syndrome or secondary fibromyalgia".

In a study conducted on 92 children with IMRD who have had COVID-19 (13), 10% had a relapse of IMRD after infection. The relapse was mild in four and moderate in five cases. One patient had a severe relapse of ARD and required hospitalization, without association with COVID-19 clinical presentation.

397 Similar to other several viral infections, SARS-CoV-2 infection could be potential trigger of reactive and autoimmune diseases by inducing type II and type IV 398 399 hypersensitivity reactions, leading to autoantibodies production and autoimmune 400 diseases development as long-term complications (18), and in patients with pre-existing IMRD, it may be difficult to identify whether it is a flare of the disease or a post-401 402 infection manifestation. A recent study evaluated the effects of COVID-19 on the 403 development and progression of RA using a collagen-induced arthritis (CIA) animal model. The incidence and severity of RA in CIA mice were slightly increased by 404 SARS-CoV-2 spike protein in vivo. In addition, the levels of autoantibodies and 405 406 thrombotic factors, such as anti-CXC chemokine ligand 4 (CXCL4, also called PF4) antibodies and anti-phospholipid antibodies were significantly increased by SARS-407 408 CoV-2 spike protein. Furthermore, tissue destruction and inflammatory cytokine level in joint tissue were markedly increased in CIA mice by SARS-CoV-2 spike protein, 409 suggesting that COVID-19 accelerates the development and progression of RA by 410 411 increasing inflammation, autoantibody production, and thrombosis(19).

In an Italian study, 122 consecutive post-COVID-19 cases were evaluated, with the onset of the rheumatic manifestations within 4 weeks from SARS-CoV-2 infection as an inclusion criterion. In this group, it was identified that most patients had inflammatory joint disease (52.5%); 19.7% of cases were diagnosed with connective

20

416 tissue diseases and 6.6% of cases with vasculitis. It is interesting to note that in this same cohort, patients with inflammatory manifestations post-COVID-19 vaccine were 417 evaluated, and this group had a higher prevalence of patients classified as polymyalgia 418 419 rheumatica (PMR, 33.1% vs. 21.3%, p=0.032) (14). Another study evaluated the 420 presence of arthritis associated with COVID-19 by ultrasound in 10 patients with (n=4) 421 and without previous rheumatic disease (n=6). In the group without previous disease, 4 of the 6 patients presented arthritis for 4 to 16 weeks after infection, comparable to 422 423 reactive arthritis. One of them developed late-onset rheumatoid arthritis. In the group 424 with previous disease, synovitis and tenosynovitis with positive power Doppler were observed, suggesting a possible flare of the disease after COVID-19 (20). 425

A major concern when interpreting the musculoskeletal symptoms in these 426 patients is the possibility of developing post-Covid syndrome, also known as long 427 428 Covid. More than 20% of subjects surviving acute COVID-19 may suffer from persisting symptoms and develop new ones after one month and about 5% of all 429 430 infected individuals develop long-term complications after 6 months, possible due to 431 tissue damage, viral reservoirs, autoimmunity, and persistent inflammation (21, 22). The clinical presentation in these cases, such as fatigue and joint pain, may mimic a 432 disease flare, thereby complicating the decision-making regarding treatment's change. 433

Recent systematic review showed that the prevalence of arthralgia ranges from 2% to 65% within a time frame varying from 4 weeks to 12 months after COVID-19. Inflammatory arthritis has been reported with various clinical phenotypes, including RA-like pattern as other prototypical viral arthritis, as well as polymyalgia-like, or acute monoarthritis and oligoarthritis of large joints resembling reactive arthritis or SpA style (23).

21

An Iranian study evaluated the prevalence of musculoskeletal symptoms in 239 patients after the acute phase of COVID-19 and its associated factors, using an online questionnaire. Almost all of them (98.74%) had experienced at least one musculoskeletal symptom after recovering from COVID-19, and the most common symptom was fatigue (91.2%), followed by myalgia, headache, and low back pain. High BMI, hospitalization, and ICU admission were associated with a higher risk of musculoskeletal symptoms (24).

Besides musculoskeletal symptoms, patients could develop psychological distress after COVID-19, such as depression, anxiety, and stress, symptoms that could also be present in IMRD. In our patients, the frequency of these symptoms in IMRD post COVID-19 was significantly higher than in patients who did not have the infection. Some authors suggested that the term of long COVID is unappropriated and should be replaced by fibromyalgia-like post-COVID syndrome (2).

We acknowledge the limitations of our study, such as the fact we have the 453 FACIT and DASS 21 scores only at the last visit and no possibility of comparison with 454 455 the pre-COVID status. Since the study began in the first months of the pandemic, we did not know yet that these outcomes were important. We decided to include it after the 456 457 first studies were published demonstrating the association of these symptoms with SARS-CoV-2 infection. However, we know that fatigue, depression, anxiety, and stress 458 are frequent symptoms in patients with IMRD and we have a group that did not have 459 460 COVID-19 as a comparator, and in the group with COVID-19 these scores were significantly worse. In addition, the greater political and economic instability 461 experienced in our country may have had a direct impact on psychological distress as 462 a bias. On the other hand, we have a representative sample, from various regions of 463 464 Brazil, with a follow-up period of 6 months, compared with a group of patients with

22

465 IMRD matched by sex and age, for the same epidemiological period, one of the main466 strengths of our study.

467

468 Conclusions

Our observational data underscore the complex interplay between COVID-19 and immune-mediated rheumatic diseases (IMRD). While disease activity scores may not exhibit significant differences, individuals with post-COVID-19 IMRD may undergo noteworthy deterioration in psychological well-being. The variations in reports regarding IMRD flares and the potential triggering role of SARS-CoV-2 in autoimmune manifestations underscore the need for thorough clinical assessment and a comprehensive approach to their management.

476

477 Acknowledgements

478 All ReumaCoV Brazil researchers

479

480

481 **References**

- 482
- 1. Miledi S, Bouzid S, Fazaa A, Sallemi M, Bousaa H, Ben Abdelghani K, Laatar A.
- 484 COVID-19 in Patients with Systemic Inflammatory Diseases: Impact on Disease Activity.
- 485 Curr Rheumatol Rev. 2023;19(3):330-5.
- 486 2. Mariette X. Long COVID: a new word for naming fibromyalgia? Ann Rheum Dis.
 487 2024;83(1):12-4.

488	3.	Marques (C, Kakehasi	AM,	Gomides .	APM, Paiva	a EDS, Do	s Reis Neto	o ET, Pile	eggi
-----	----	-----------	-------------	-----	-----------	------------	-----------	-------------	------------	------

- 489 GCS, et al. A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory
- 490 Diseases Infected by SARS-CoV-2 (ReumaCoV-Brasil Registry): Protocol for a Prospective,
- 491 Observational Study. JMIR Res Protoc. 2020;9(12):e24357.
- 492 4. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS.
- 493 Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis:
- 494 validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806.
- 495 5. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity
 496 index 2000. J Rheumatol. 2002;29(2):288-91.
- 497 6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new
- 498 approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing
- 499 Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
- 500 7. Konzett V, Kerschbaumer A, Smolen JS, Kristianslund EK, Provan SA, Kvien TK,
 501 Aletaha D. Definition of rheumatoid arthritis flare based on SDAI and CDAI. Ann Rheum
 502 Dis. 2024;83(2):169-76.
- Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The use of
 Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and
 minimal clinically meaningful change based on data from a large cohort of systemic lupus
 erythematosus patients. Rheumatology (Oxford). 2011;50(5):982-8.
- Gossec L, Portier A, Landewe R, Etcheto A, Navarro-Compan V, Kroon F, et al.
 Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and
 ASDAS-CRP: an ASAS initiative. Ann Rheum Dis. 2016;75(6):991-6.

24

510 10. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a

new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol.

512 1997;34(3 Suppl 2):13-9.

513 11. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress

514 Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J

515 Clin Psychol. 2005;44(Pt 2):227-39.

516 12. Sandhu NK, Ravichandraan N, Nune A, Day J, Sen P, Nikiphorou E, et al. Flares of

517 autoimmune rheumatic disease following COVID-19 infection: Observations from the

518 COVAD study. Int J Rheum Dis. 2024;27(1):e14961.

519 13. Sinkovec Savsek T, Zajc Avramovic M, Avcin T, Korva M, Avsic Zupanc T, Toplak

520 N. Disease relapse rate in children with autoimmune rheumatic diseases after COVID-19

521 infection and vaccination. Pediatr Rheumatol Online J. 2023;21(1):46.

522 14. Ursini F, Ruscitti P, Addimanda O, Foti R, Raimondo V, Murdaca G, et al.

523 Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19

vaccination: a report of 267 cases from the COVID-19 and ASD group. RMD Open.

525 2023;9(2).

van Kessel SAM, Olde Hartman TC, Lucassen P, van Jaarsveld CHM. Post-acute and
long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract.
2022;39(1):159-67.

Bingham CO, 3rd, Pohl C, Woodworth TG, Hewlett SE, May JE, Rahman MU, et al.
Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9
Special Interest Group). J Rheumatol. 2009;36(10):2335-41.

2	-
1	5
~	-

532 17. Coskun Benlidayi I. Fibromyalgia interferes with disease activity and biol	ogical
--	--------

therapy response in inflammatory rheumatic diseases. Rheumatol Int. 2020;40(6):849-58.

- 534 18. Votto M, Castagnoli R, Marseglia GL, Licari A, Brambilla I. COVID-19 and
- autoimmune diseases: is there a connection? Curr Opin Allergy Clin Immunol.

536 2023;23(2):185-92.

537 19. Lee AR, Woo JS, Lee SY, Lee YS, Jung J, Lee CR, et al. SARS-CoV-2 spike protein

538 promotes inflammatory cytokine activation and aggravates rheumatoid arthritis. Cell

- 539 Commun Signal. 2023;21(1):44.
- 540 20. Vogler D, Ruscitti P, Navarini L, Giacomelli R, Iagnocco A, Hoff P, et al. Diagnosis

of COVID-19 associated arthritis in patients with or without underlying rheumatic and

542 musculoskeletal disease supported by musculoskeletal ultrasound: a case series from three

European centres. Clin Exp Rheumatol. 2023;41(3):656-66.

- 544 21. Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z,
- 545 Ashbaugh C, et al. Estimated Global Proportions of Individuals With Persistent Fatigue,

546 Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020

547 and 2021. JAMA. 2022;328(16):1604-15.

548 22. Cervia-Hasler C, Bruningk SC, Hoch T, Fan B, Muzio G, Thompson RC, et al.

549 Persistent complement dysregulation with signs of thromboinflammation in active Long

- 550 Covid. Science. 2024;383(6680):eadg7942.
- 551 23. Ciaffi J, Vanni E, Mancarella L, Brusi V, Lisi L, Pignatti F, et al. Post-Acute

552 COVID-19 Joint Pain and New Onset of Rheumatic Musculoskeletal Diseases: A Systematic

553 Review. Diagnostics (Basel). 2023;13(11).

- 554 24. Azadvari M, Haghparast A, Nakhostin-Ansari A, Emami Razavi SZ, Hosseini M.
- Musculoskeletal symptoms in patients with long COVID: A cross-sectional study on Iranian 555
- patients. Heliyon. 2022;8(8):e10148. 556

557